Lineage Cell Therapeutics (LCTX) Non-Current Debt (2015 - 2017)
Lineage Cell Therapeutics (LCTX) posted quarterly Non-Current Debt of $18000.0 for Q4 2017, down 85.0% year-over-year from $120000.0 in Q4 2016, and down 59.09% quarter-over-quarter from $44000.0 in Q3 2017.
Lineage Cell Therapeutics (LCTX) Non-Current Debt (2015 - 2017) Analysis & Trends
Lineage Cell Therapeutics' Non-Current Debt history runs 3 years deep, the most recent figure standing at $18000.0 for Q4 2017.
- In Q4 2017, Non-Current Debt fell 85.0% year-over-year to $18000.0; the TTM figure through Dec 2017 stood at $18000.0 (down 85.0% YoY), while the FY2017 annual figure was $18000.0, down 85.0% from the prior year.
- Non-Current Debt for Q4 2017 stood at $18000.0, down from $44000.0 in the prior quarter.
- The five-year high for Non-Current Debt was $268000.0 in Q3 2015, with the low at $18000.0 in Q4 2017.
- The 3-year median for Non-Current Debt is $146500.0 (2016), against an average of $142600.0.
- The sharpest annual moves came in 2016 and 2017: Non-Current Debt sank 35.45% in 2016, then slumped 85.0% in 2017.
- Lineage Cell Therapeutics' Non-Current Debt stood at $220000.0 in 2015, then sank by 45.45% to $120000.0 in 2016, then plunged by 85.0% to $18000.0 in 2017.
- Business Quant data shows LCTX's Non-Current Debt at $18000.0 in Q4 2017, $44000.0 in Q3 2017, and $95000.0 in Q2 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 882.16 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 8.96 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Lineage Cell Therapeutics | 270.61 Mn | 212.77 Mn | 1.07 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2017 | 18,000.00 |
| Sep 30, 2017 | 44,000.00 |
| Jun 30, 2017 | 95,000.00 |
| Mar 31, 2017 | 95,000.00 |
| Dec 31, 2016 | 120,000.00 |
| Sep 30, 2016 | 173,000.00 |
| Jun 30, 2016 | 173,000.00 |
| Mar 31, 2016 | 220,000.00 |
| Dec 31, 2015 | 220,000.00 |
| Sep 30, 2015 | 268,000.00 |